REFERENCES

Berger, M. L., Bingefors, K., Hedblom, E. C., Pashos, C. L., & Torrance, G.W (2003). Health care cost, quality, and outcomes: ISPOR book of terms. Lawrenceville, NJ: International Society for Pharmacoeconomics and Outcomes Research.

Braithwaite, R. S., Meltzer, D. O., King, J. T., Leslie, D., & Roberts, M. S. (2008). What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Medical Care, 46(4), 349-356. doi:10.1097/MLR.0b013e31815c31a7

Briggs, A., Sculpher, M., & Claxton, K. (2006). Decision modelling for health economic evaluation. Oxford, England: Oxford University Press.

Dearing, J. W (2009). Applying diffusion of innovation theory to intervention development. Research on Social Work Practice, 19(5), 503-518. doi:10.1177/1049731509335569

Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (2011). Pharmacotherapy: A pathophysiologic approach (8th ed.). New York, NY: McGraw-Hill.

Drummond, M. E, & Jefferson, T. O. (1996). Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working party. British Medical Journal, 313, 275-283.

Drummond, M. E, Sculpher, M. J., Torrance, G. W, O’Brien, B. J., & Stoddart, G. L. (2005). Methods for the economic evaluation of health care programs (3rd ed.). Oxford, England: Oxford University Press.

Fryback, D. G., Dasbach, E. J., Klein, R., Klein, B. E., Dorn, N., Peterson, K., & Martin, P A. (1993). The beaver dam health outcomes study: Initial catalog of health-state quality factors. Medical Decision Making, 13(2), 89-102.

Gafni, A., Walter, S. D., Birch, S., & Sendi, P (2008). An opportunity cost approach to sample size calculation in cost-effectiveness analysis. Health Economics, 17(1), 99-107.

Gitlin, L. N., Harris, L. F, McCoy, M., Chernett, N. L., Jutkowitz, E., & Pizzi, L. T. (2012). A community-integrated home-based depression intervention for older African Americans: Description of the beat the blues randomized trial and intervention costs. BMC Geriatrics, 12(4), 1-11. doi:10.1186/1471-2318-12-4

Gitlin, L. N., Jutkowitz, E., Hodgson, N., & Pizzi, L. (2010). The cost-effectiveness of a nonpharmacologic intervention for individuals with dementia and family caregivers: The tailored activity program. American Journal of Geriatric Psychiatry, 18(6), 510-519. doi:10.1097/JGP0b013e3181c37d13

Gitlin, L. N., Winter, L., Vause Earland, T., Adel Herge, E., Chernett, N. L., Piersol, C. V, & Burke, J. P. (2009). The tailored activity program to reduce behavioral symptoms in individuals with dementia: Feasibility, acceptability, and replication potential. Gerontologist, 49(3), 428-439. doi:10.1093/geront/gnp087

Glick, H. A. (2011). Sample size and power for cost-effectiveness analysis (part 1). Pharmaco- Economics, 29(3), 189-198. doi:10.2165/11585070-000000000-00000

Glossary. (2015). Retrieved from http://www.cigna.com/glossary

Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (1996). Cost-effectiveness in health and medicine. New York, NY: Oxford University Press.

Horsman, J., Furlong, W, Feeny, D., & Torrance, G. (2003). The health utilities index (HUI): Concepts, measurement properties and applications. Health and Quality of Life Outcomes, 1,54. doi:10.1186/1477-7525-1-54

Hunink, M. G. M., & Glasziou, P P (2001). Decision making in health and medicine: Integrating evidence and values. Cambridge, England: Cambridge University Press.

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., . . . Loder, E. (2013a). Consolidated health economic evaluation reporting standards (CHEERS) statement. PharmacoEconomics, 31(5), 361-367. doi:10.1007/s40273-013-0032-y

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., . . . Loder, E. (2013b). Consolidated health economic analysis reporting standards (CHEERS) statement. Value in Health, 16(2), e1-e5. doi:10.1016/j.jval.2013.02.010

Kaplan, A. (1998). The conduct of inquiry: Methodology for behavioral science. Township, NJ: Transaction Publishers.

Mahoney, D. F, Jones, R. N., Coon, D. W, Mendelsohn, A. B., Gitlin, L. N., & Ory, M. (2003). The caregiver vigilance scale: Application and validation in the resources for enhancing Alzheimer’s caregiver health (REACH) project. American Journal of Alzheimer’s Disease and Other Dementias, 18(1), 39-48.

Meltzer, D. (1997). Accounting for future costs in medical cost-effectiveness analysis. Journal of Health Economics, 16(1), 33-64.

National fee analyzer (2014). West Valley City, UT: Ingenix.

Neumann, P J., Goldie, S. J., & Weinstein, M. C. (2000). Preference-based measures in economic evaluation in health care. Annual Review of Public Health, 21, 587-611.

Nyman, J. A. (2004). Should the consumption of survivors be included as a cost in cost- utility analysis? Health Economics, 13(5), 417-427.

Owens, D. K., Qaseem, A., Chou, R., & Shekelle, P (2011). High-value, costconscious health care: Concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Annals of Internal Medicine, 154(3), 174-180. doi:10.7326/0003-4819-154-3-201102010-00007

Petrou, S., & Gray, A. (2011). Economic evaluation alongside randomised controlled trials: Design, conduct, analysis, and reporting. BMJ, 342, 2.

Pizzi, L. T., & Lofland, J. H. (2006). Economic analysis in US healthcare: Principles and applications. Sudbury, MA: Jones and Bartlett.

Ramsey, S., Willke, R., Briggs, A., Brown, R., Buxton, M., Chawla, A., . . . Reed, S. (2005). Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA task force report. Value in Health, 8(5), 521-533. doi: 10.1111/j. 1524-4733.2005.00045.x

Russell, L. B., Gold, M. R., Siegel, J. E., Daniels, N., & Weinstein, M. C. (1996). The role of cost-effectiveness analysis in health and medicine. Journal of the American Medical Association, 276(14), 1172-1177. doi:10.1001/jama.1996.03540140060028

Schneider, L. S., Tariot, P N., Lyketsos, C. G., Dagerman, K. S., Davis, K. L., Davis, S., . . . Lieberman, J. A. (2001). National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. American Journal of Geriatric Psychiatry, 9(4), 346-360. doi:10.1097/00019442-200111000-00004

Shaw, J. W, Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43(3), 203-220.

Siegel, J. E., Weinstein, M. C., Russell, L. B., & Gold, M. R. (1996). Recommendations for reporting cost-effectiveness analyses. Journal of the American Medical Association, 276(16), 1339-1341. doi:10.1001/jama.1996.03540160061034

Wang, Z., Salmon, J. W, & Walton, S. M. (2004). Cost-effectiveness analysis and the formulary decision-making process. Journal of Managed Care Pharmacy, 10(1), 48-59.

Weinstein, M. C., Siegel, J. E., Gold, M. R., Kamlet, M. S., & Russell, L. B. (1996). Recommendations of the panel on cost-effectiveness in health and medicine. Journal of the American Medical Association, 276(15), 1253-1258. doi:10.1001/jama.1996.0354015 0055031

Weinstein, M. C., & Stason, W B. (1977). Foundations of cost effectiveness analysis for health and medical practices. New England Journal of Medicine, 296(13), 716-721. doi:10.1056/NEJM197703312961304

Wimo, A., & Winblad, B. (2003). Resource utilization in dementia: “RUD lite.” Brain Aging, 3(1), 48-59.

 
Source
< Prev   CONTENTS   Source   Next >